The Allogenic Vaccine

The modified allogeneic vaccine consists of a tumor cell line that has undergone changes to improve its recognition by the immune system, and to enhance the response it elicits in the patient.

MELANOMA

This recently developed vaccine for melanoma patients can be delivered in cases where melanoma cells from the patient are not available. Due to its unique characteristics, this vaccine is appropriate for a large percentage of the population.

Results from a first series of twenty patients are highly satisfactory in terms of safety, lack of toxicity, and the level of efficacy attained.

Eligibility
The treatment program is intended for patients with stage IV melanoma who have undergone surgery to remove one or more metastases and show no evidence of additional tumor sites.

Other cancers

A vaccine has been recently developed for the treatment of colon, ovary, breast, gastric, lung, kidney and prostate cancers and for sarcoma and merkel cell carcinoma. This vaccine, due to its unique characteristics, is appropriate for a large percentage of the population.

Eligibility
The treatment program is intended for patients with stage IV cancer who have undergone surgery to remove one or more metastases and show no evidence of additional tumor sites.